Butein; CCG208298; CCG 208298; CS-5675; NSC 652892; CCG-208298; CS5675; AC1NQY7L; AC1N-QY7L; AC1N QY7L; CS-5675; NSC-652892; NSC652892
Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Butein (NSC 652892; CCG-208298; CS5675; AC1NQY7L) is a naturally occuring plant polyphenol and chalconoid isolated from Rhus verniciflua with a broad spectrum of pharmacological effects such as antiinflammatory, antioxidative, aldose reductase and advanced glycation endproducts inhibitory and anticancer activities. It is a chalcone of the chalconoid that is present in Dahlia, Coreopsis, Butea, and Toxicodendron vernicifluum. Butein has the ability to prevent NF-κB, STAT3, protein tyrosine kinase, and EGFR from being activated.
Targets |
EGFR (IC50 = 16 μM); PDE4 (IC50 = 10.4 μM)
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
Butein prevented cisplatin-induced activation of extracellular signal-regulated kinases (ERKs), p38 kinases, and AKT.
|
|
Cell Assay |
In a 96-well plate, the cells (5 x 103 / mL) are cultured in triplicate with or without the indicated concentration of Butein in a final volume of 0.2 mL for varying durations at 37 °C. Each well is then filled with 20 μL of MTT solution (5 mg/mL in PBS). A 2-hour incubation period at 37 °C is followed by the addition of 0.1 mL of lysis buffer (20% SDS, 50% dimethylformamide), an overnight incubation period at 37 °C, and a plate reader measurement of the optical density at 570 nm.
|
|
Animal Protocol |
Human hepatocellular carcinoma xenografts HepG2
2 mg/kg intraperitoneal injection, 5 doses per week for 3 consecutive weeks |
|
References |
[1]. Biochem Biophys Res Commun . 1998 Apr 17;245(2):435-8. [2]. J Biol Chem . 2007 Jun 15;282(24):17340-50. [3]. Biochem Biophys Res Commun . 2004 Oct 8;323(1):125-32. [4]. FEBS Lett . 2008 Jun 11;582(13):1821-8. [5]. Clin Cancer Res . 2011 Mar 15;17(6):1425-39. |
Molecular Formula |
C15H12O5
|
|
---|---|---|
Molecular Weight |
272.2528
|
|
Exact Mass |
272.07164
|
|
Elemental Analysis |
C, 66.17; H, 4.44; O, 29.38
|
|
CAS # |
487-52-5
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)O
|
|
InChi Key |
AYMYWHCQALZEGT-ORCRQEGFSA-N
|
|
InChi Code |
InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+
|
|
Chemical Name |
(E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 1.67 mg/mL (6.13 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL | |
5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL | |
10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Butein inhibits constitutively active STAT3 in HepG2 cells. Clin Cancer Res . 2011 Mar 15;17(6):1425-39. td> |
Butein downregulates IL-6–induced p-STAT3 in HCC cells. Clin Cancer Res . 2011 Mar 15;17(6):1425-39. td> |
Butein suppresses STAT3-regulated gene products involved in proliferation, survival, and angiogenesis. Clin Cancer Res . 2011 Mar 15;17(6):1425-39. td> |
Butein suppresses the proliferation, activates caspase-3, and potentiates apoptosis induced by doxorubicin and paclitaxel. Clin Cancer Res . 2011 Mar 15;17(6):1425-39. td> |
(A) Effects of butein on ERK1/2 activation. BLS(M) and BLX(E) cells were treated by butein (20 μM) for the indicated times. FEBS Lett . 2008 Jun 11;582(13):1821-8. td> |
Butein reversed mesenchymal-like phenotype of BLS(M) cells. FEBS Lett . 2008 Jun 11;582(13):1821-8. td> |
Butein reverted EMT-like phenotype induced by TNF-α in BLX(E) cells. FEBS Lett . 2008 Jun 11;582(13):1821-8. td> |